{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:57:20Z","timestamp":1761897440720,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-PHUC-001"],"award-info":[{"award-number":["ANR-11-PHUC-001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use of pneumocystis prophylaxis. Conclusion: The low rates of vaccination indicate the need to improve physician and MM patient adherence and education regarding vaccination.<\/jats:p>","DOI":"10.3390\/vaccines8040722","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T07:49:54Z","timestamp":1606895394000},"page":"722","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7354-0525","authenticated-orcid":false,"given":"Guilhem","family":"Tournaire","sequence":"first","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, CHU de Toulouse, 31000 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Conte","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, CHU de Toulouse, 31000 Toulouse, France"},{"name":"UMR1027, Inserm, Universit\u00e9 Paul Sabatier, 31330 Toulouse, France"},{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paul Sabatier, 31000 Toulouse, France"},{"name":"Centre Midi-Pyr\u00e9n\u00e9es de Pharmacovigilance, de Pharmaco\u00e9pid\u00e9miologie et d\u2019Informations sur le M\u00e9dicament, Centre Hospitalier Universitaire de Toulouse, 31000 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie et de m\u00e9decine Interne, Institut Universitaire du Cancer-Oncopole, CHU de Toulouse, 31000 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre-Mester","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, CHU de Toulouse, 31000 Toulouse, France"},{"name":"UMR1027, Inserm, Universit\u00e9 Paul Sabatier, 31330 Toulouse, France"},{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paul Sabatier, 31000 Toulouse, France"},{"name":"Centre Midi-Pyr\u00e9n\u00e9es de Pharmacovigilance, de Pharmaco\u00e9pid\u00e9miologie et d\u2019Informations sur le M\u00e9dicament, Centre Hospitalier Universitaire de Toulouse, 31000 Toulouse, France"},{"name":"INSERM Centre d\u2019Investigation Clinique 1436 Toulouse, Centre d\u2019Investigation Clinique de Toulouse, Centre Hospitalier Universitaire de Toulouse, 31000 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, CHU de Toulouse, 31000 Toulouse, France"},{"name":"UMR1027, Inserm, Universit\u00e9 Paul Sabatier, 31330 Toulouse, France"},{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paul Sabatier, 31000 Toulouse, France"},{"name":"Centre Midi-Pyr\u00e9n\u00e9es de Pharmacovigilance, de Pharmaco\u00e9pid\u00e9miologie et d\u2019Informations sur le M\u00e9dicament, Centre Hospitalier Universitaire de Toulouse, 31000 Toulouse, France"},{"name":"INSERM Centre d\u2019Investigation Clinique 1436 Toulouse, Centre d\u2019Investigation Clinique de Toulouse, Centre Hospitalier Universitaire de Toulouse, 31000 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.blre.2013.04.001","article-title":"Management of older adults with multiple myeloma","volume":"27","author":"Palumbo","year":"2013","journal-title":"Blood Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0609.1998.tb01075.x","article-title":"The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance","volume":"61","author":"Gregersen","year":"1998","journal-title":"Eur. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: A population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J. Clin. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CVI.00021-11","article-title":"Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"18","author":"Karlsson","year":"2011","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4065\/77.8.813","article-title":"Current therapy for multiple myeloma","volume":"77","author":"Rajkumar","year":"2002","journal-title":"Mayo Clin. Proc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: What interest for medical research?","volume":"36","author":"Moulis","year":"2015","journal-title":"Rev. Med. Interne."},{"key":"ref_18","first-page":"4791","article-title":"Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin\u2019s lymphoma: A cohort study of the French national health insurance database","volume":"24","author":"Conte","year":"2016","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e6189","DOI":"10.1097\/MD.0000000000006189","article-title":"Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry","volume":"96","author":"Palmaro","year":"2017","journal-title":"Medicine"},{"key":"ref_20","unstructured":"HCSP (2010). Actualisation de la Liste des Sujets Eligibles \u00e0 la Vaccination Contre la Grippe Saisonni\u00e8re, Haut Conseil de la Sant\u00e9 Publique. Available online: https:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=179."},{"key":"ref_21","unstructured":"(2019, January 31). WHOCC\u2014ATC\/DDD Index. Available online: https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.respe.2013.01.015","article-title":"Score de Charlson \u00e0 partir des donn\u00e9es du Sniiram cha\u00een\u00e9es au PMSI: Faisabilit\u00e9 et valeur pronostique sur la mortalit\u00e9 \u00e0 un an","volume":"61","author":"Bannay","year":"2013","journal-title":"Rev. D\u00c9pid\u00e9miologie Sant\u00e9 Publique"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med. Care"},{"key":"ref_25","unstructured":"HCSP (2013). Infections Invasives A Pneumocoque: Recommandations Vaccinales Pour les Personnes \u00e0 Risque, Haut Conseil de la Sant\u00e9 Publique. Available online: https:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=355."},{"key":"ref_26","unstructured":"(2018, May 28). Codes G\u00e9ographiques et Codes Pays | Publication ATIH. Available online: https:\/\/www.atih.sante.fr\/codes-geographiques-et-codes-pays."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rey, G., Jougla, E., Fouillet, A., and H\u00e9mon, D. (2009). Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: Variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health, 9.","DOI":"10.1186\/1471-2458-9-33"},{"key":"ref_28","first-page":"53","article-title":"Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study","volume":"4","author":"Alemu","year":"2017","journal-title":"J. Patient-Cent. Res. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajh.23930","article-title":"Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France","volume":"90","author":"Moulis","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_30","unstructured":"Couderc, S. (2019, May 06). Risque Infectieux des Medicaments Biologiques Versus Traitements Systemiques Conventionnels Dans le Psoriasis Modere a Severe = Infectious Risk of Biological Drugs Versus Conventional Systemic Treatements in Moderate to Severe Psoriasis, Limoges, 2015. Available online: http:\/\/aurore.unilim.fr\/ori-oai-search\/notice\/view\/unilim-ori-53243."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clml.2016.06.006","article-title":"Vaccination in Multiple Myeloma: Review of Current Literature","volume":"16","author":"Alemu","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: A nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2515\/therapie\/2014056","article-title":"Pharmacoepidemiology of Immune Thrombocytopenia: Protocols of FAITH and CARMEN studies","volume":"69","author":"Moulis","year":"2014","journal-title":"Therapie"},{"key":"ref_34","unstructured":"(2019, May 07). INPES\u2014Calendrier des Vaccinations. Available online: http:\/\/inpes.santepubliquefrance.fr\/10000\/themes\/vaccination\/calendrier\/calendrier-vaccination.asp."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4161\/hv.4.4.5437","article-title":"Sustaining immunity after immunization against encapsulated bacteria","volume":"4","author":"Pollard","year":"2008","journal-title":"Hum. Vaccin."},{"key":"ref_36","unstructured":"HCSP (2014). Vaccination des Personnes Immunod\u00e9prim\u00e9es ou Aspl\u00e9niques. Recommandations Actualis\u00e9es, Haut Conseil de la Sant\u00e9 Publique. Available online: https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=504."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00441","DOI":"10.1016\/j.heliyon.2017.e00441","article-title":"Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study","volume":"3","author":"Bahuaud","year":"2017","journal-title":"Heliyon"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/722\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:40:25Z","timestamp":1760179225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040722"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040722","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2020,12,2]]}}}